Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 17, 2026

SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial

Listen
0:00 / 0:00

Key Takeaways

  • Maintenance galinpepimut-S achieved a statistically significant OS benefit versus heterogeneous BAT options (including observation, HMA, venetoclax, and/or low-dose cytarabine) in post-salvage CR2/CRp2 AML.
  • Trial population addressed a high unmet-need setting: patients in second or later remission who were ineligible for or unable to undergo allogeneic hematopoietic stem cell transplantation.
SHOW MORE

Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.

SELLAS Life Sciences announced on November 17, 2026, that its phase 3 REGAL trial of galinpepimut-S (GPS), a Wilms tumor 1 (WT1)-targeted immunotherapeutic cancer vaccine, met its primary end point of overall survival (OS) in patients with acute myeloid leukemia (AML).¹ GPS reduced the risk of death by 41% compared with investigator's choice of best available treatment (BAT). Median OS was 24.0 months with GPS vs 14.7 months with BAT (hazard ratio, 0.59; 2-sided p=.035).¹

Key facts

  • Drug: galinpepimut-S (GPS; SELLAS Life Sciences)
  • Class: WT1-targeted peptide immunotherapeutic cancer vaccine
  • Indication studied: AML maintenance in CR2/CRp2 or later, transplant ineligible
  • Trial: REGAL (NCT04229979); phase 3, randomized, open-label, n=126
  • Primary end point met: Median OS 24.0 vs 14.7 months (HR, 0.59; p=.035)
  • Comparator: Investigator's choice of best available treatment
  • Safety: Mostly grade 1 or 2; injection site reactions most common
  • Regulatory status: FDA meeting planned; BLA targeted for first half of 2027
  • Origin: Licensed from Memorial Sloan Kettering Cancer Center
  • Next data: Secondary end points at an upcoming medical conference

“REGAL has delivered on its primary objective, demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with AML who have very limited options after achieving a second remission,” said Angelos Stergiou, MD, ScD h.c., president and CEO, SELLAS, in a company press release.¹

What did the REGAL trial evaluate?

REGAL (NCT04229979) is a global, randomized, open-label trial testing GPS as maintenance monotherapy in patients with AML. Eligible patients had reached a second or later complete remission (CR2 or later), or complete remission with insufficient platelet recovery (CRp2 or later), after second- or later-line salvage therapy. They also had to be ineligible for, or unable to undergo, allogeneic stem cell transplantation.¹,² A total of 126 patients were randomized 1:1 to GPS or BAT, which included observation, a hypomethylating agent, venetoclax, and/or low-dose cytarabine.¹

The topline analysis was run after the prespecified 80 deaths, as set out in the trial's statistical analysis plan.¹ The treatment arms were balanced for prognostic stratification factors. Few patients went on to hematopoietic stem cell transplantation, and they were evenly split between the arms.¹

What was the safety profile?

GPS was generally well tolerated, with a safety profile consistent with prior clinical experience and no new safety signals.¹ Treatment-related adverse events were mostly grade 1 or 2, most commonly local injection site reactions.¹

How does GPS work?

GPS is an investigational off-the-shelf vaccine licensed from Memorial Sloan Kettering Cancer Center. It consists of 4 WT1-derived peptides designed to stimulate CD4+ and CD8+ T-cell responses across multiple human leukocyte antigen types.¹ WT1 is expressed in a broad range of hematologic malignancies and solid tumors, including AML, and GPS is intended to direct the immune system against residual WT1-expressing cancer cells.¹ In an earlier phase 2 trial of 22 patients with AML, 9 of 14 tested patients (64%) had a CD4 or CD8 immune response. The most common toxicities were grade 1 or 2 injection site reactions (46%).³

Why does this matter for AML?

The REGAL steering committee said patients with AML in second remission who cannot undergo allogeneic stem cell transplantation face poor survival outcomes and need new treatment approaches.¹ SELLAS plans to meet with FDA to discuss an accelerated filing strategy. It is preparing a biologics license application (BLA) for submission in the first half of 2027.¹ Full analyses of the secondary end points are underway, including leukemia-free survival, measurable residual disease, and T-cell immune response dynamics. They will be presented at a medical conference and submitted for peer-reviewed publication.¹

What are the limitations?

The results are topline and have not been peer reviewed, and the release does not report a confidence interval for the hazard ratio. REGAL was open-label, and the control arm combined several options, including observation, which makes comparison with any single active therapy difficult. The trial enrolled 126 patients, and secondary end point results have not been disclosed.

References

  1. SELLAS Life Sciences. SELLAS Life Sciences announces positive pivotal phase 3 REGAL trial data showing immunotherapeutic cancer vaccine, galinpepimut-S (GPS), demonstrated a statistically significant and clinically meaningful improvement in overall survival in patients with acute myeloid leukemia. Press release. Published November 17, 2026. Accessed November 17, 2026. https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Announces-Positive-Pivotal-Phase-3-REGAL-Trial-Data-Showing-Immunotherapeutic-Cancer-Vaccine-Galinpepimut-S-GPS-Demonstrated-a-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Overall-Survival-in-Patients-with-A/default.aspx
  2. Galinpepimut-S versus investigator's choice of best available therapy for maintenance in AML CR2/CRp2 (REGAL). ClinicalTrials.gov; NCT04229979. Updated October 1, 2025. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT04229979
  3. Maslak PG, Dao T, Bernal Y, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224-234. doi:10.1182/bloodadvances.2017014175

Related to this article